Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers

Next Previous
Search
Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bapineuzumab (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors JANSSEN Alzheimer Immunotherapy; Janssen Research & Development

Most Recent Events

  • 04 Aug 2022 Results from NCT00574132 and NCT00575055 quantifying the impact of study partner (SP) type on the variance of SP-reported Disability Assessment for Dementia scores , presented at the Alzheimer's Association International Conference 2022
  • 02 Feb 2018 Results of Pooled analysis (n=1512) from this and another phase III trial (CT profile 700029662) assessing amyloid-related imaging abnormalities with edema/effusion treated with bapineuzumab published in the Neurology.
  • 11 Sep 2012 Results presented at the 16th Congress of the European Federation of Neurological Societies.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top